Article
Evaluation of the EMPAR study population on the basis of metabolic phenotypes of selected pharmacogenes.
The pharmacogenomics journal - 1 Mar 2022
Fracowiak Jochen, Huebner Tatjana, Heß Steffen, Roethlein Christoph, Langner Daria, Schneider Udo, Falkenberg Felix, Scholl Catharina, Linder Roland, Stingl Julia, Haenisch Britta, Steffens Michael
Abstract excerpt
The impact of genetic variability of pharmacogenes as a possible risk factor for adverse drug reactions is elucidated in the EMPAR (Einfluss metabolischer Profile auf die Arzneimitteltherapiesicherheit in der Routineversorgung/English: influence of metabolic profiles on the safety of drug therapy in routine care) study. EMPAR evaluates possible associations of pharmacogenetically predicted metabolic profiles...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.